-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 20, 2021, Menarini Group and Radius Health announced that the selective estrogen receptor degrading agent (SERD) elacestrant has obtained positive results in a phase 3 clinical trial
Breast cancer is one of the most common forms of cancer in the United States
The study included 466 patients who had previously received first-line or second-line endocrine therapy, including cyclin-dependent kinase (CDK) 4/6 inhibitor therapy
Reference materials:
[1] Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer.
(The original text has been deleted)